KORU Medical Systems, Inc.

Listed Company

KRMDCIK 0000704440NasdaqNon-AcceleratedSmaller ReportingSurgical & Medical Instruments & ApparatusDelawareFY ends Dec 31

Period

FY 2025

Revenue

$41.13M

Net Income

$-2.64M

Total Assets

$28.20M

Equity

$17.05M

Shares Out

45.93M

Op. Cash Flow

$462.4K

KRMD$4.10+23.87% · past yearDBEQ Basic

Daily closing prices

Business

KORU Medical Systems develops, manufactures and commercializes mechanical large-volume subcutaneous infusion systems, primarily the FREEDOM System with syringe drivers, needle sets and tubing for drug delivery. Core products deliver immunoglobulin therapies for Primary Immunodeficiency Diseases and Chronic Inflammatory Demyelinating Polyneuropathy, with FDA clearance for multiple on-label drugs. Revenue streams include domestic and international product sales through distributors and specialty pharmacies, plus pharma services and non-recurring engineering fees from biopharmaceutical companies conducting clinical trials and customizing the FREEDOM System for novel therapies.

Summary from 10-K filed 2026-03-12

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
NET REVENUES	41	34	29	28	23
Cost of goods sold	16	12	12	13	10
Gross Profit	26	21	17	15	14
Selling, general and administrative	23	22	20	21	18
Research and development	4	5	6	5	2
Depreciation and amortization	810,500	888,473	870,390	587,137	463,130
Total Operating Expenses	29	28	27	26	21
Net Operating Loss	−3	−6	−10	−11	−7
Income/(loss) on foreign currency exchange	53,097	−45,991	−5,124	−39,874	−28,905
Other income/(expense)	9,906	−16,160	561,328	145,587	13,083
Interest income, net	293,403	444,642	—	—	—
TOTAL OTHER INCOME	356,406	382,491	496,397	105,713	665,094
LOSS BEFORE TAXES	−3	−6	—	—	—
Income tax expense	−21,890	−2,893	−4	2	2
NET LOSS	−3	−6	−14	−9	−5
Basic (per share)	−0.06	−0.13	−0.3	−0.19	−0.1
Diluted (per share)	−0.06	−0.13	−0.3	−0.19	−0.1
Basic (shares)	46	46	46	45	44
Diluted (shares)	46	46	46	45	44

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	9	10	11	17	25
Accounts receivable, net	6	6	4	4	4
Inventory, net	4	3	3	6	6
Other receivables	319,955	277,193	28,889	972,396	718,220
Prepaid expenses and other current assets	908,542	749,851	1	1	2
TOTAL CURRENT ASSETS	20	19	20	30	37
Property and equipment, net	4	4	4	4	1
Intangible assets, net of accumulated amortization of $527,949 and $458,538 at December 31, 2025 and December 31, 2024, respectively	684,841	730,279	754,361	787,182	808,813
Operating lease right-of-use assets	3	3	4	4	95,553
Other assets	98,970	98,970	98,970	102,625	19,812
TOTAL ASSETS	28	27	28	42	41
Accounts payable	2	2	975,193	2	1
Accrued expenses	5	4	2	3	3
Note payable	—	271,152	314,344	433,295	508,583
Other liabilities	27,722	29,269	512,520	257,337	90,000
Accrued payroll and related taxes	531,972	811,401	462,941	542,399	160,603
Finance lease liability	124,913	115,587	109,540	98,335	—
Operating lease liability	413,448	400,258	368,313	345,834	95,553
TOTAL CURRENT LIABILITIES	8	7	4	7	5
Finance lease liability, net current portion	78,675	202,613	316,623	394,283	—
Operating lease liability, net of current portion	3	3	3	4	—
TOTAL LIABILITIES	11	10	8	11	5
Commitments and contingencies (Refer to Note 9)	—	—	—	—	—
Common stock, $0.01 par value, 75,000,000 shares authorized, 49,790,934 and 49,377,617 shares issued; 46,370,432 and 45,957,115 shares outstanding at December 31, 2025, and December 31, 2024, respectively	497,909	493,776	490,899	488,619	480,441
Additional paid-in capital	52	50	47	44	41
Treasury stock, 3,438,526 and 3,438,526 shares at December 31, 2025 and December 31, 2024, respectively, at cost	−4	−4	−4	−4	−4
Accumulated Deficit	−32	−29	−23	−10	−910,069
TOTAL STOCKHOLDERS EQUITY	17	17	20	31	37
TOTAL LIABILITIES AND STOCKHOLDERS EQUITY	28	27	28	42	41

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Stock-based compensation expense and warrant expense	3	3	3	3	3
Loss/(Gain) on disposal of fixed assets	−6,700	16,160	59,807	—	−1,009
Non-cash leasing charges	−97,840	243,394	−21,988	—	—
Increase in accounts receivable	−489,199	−2	−486,327	34,002	−1
Decrease/(Increase) in inventory	−874,462	677,632	3	−298,529	723,434
Decrease/(Increase) in prepaid expenses and other assets	−196,682	220,133	242,599	28,776	−761,041
Increase in accounts payable	617,504	674,776	−1	1	602,613
Increase/(Increase) in accrued payroll and related taxes	−279,429	348,460	−79,458	381,796	−126,527
Decrease in other liabilities	−1,547	−483,250	255,183	167,337	90,000
Increase in accrued expenses	904,647	2	−1	180,237	99,291
NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES	462,405	−319,718	−5	−5	−4
Purchases of property and equipment	−932,517	−1	−782,949	−3	−346,178
Proceeds on disposals of property and equipment	6,700	8,500	—	—	—
Purchases of intangible assets	−23,973	−44,115	−31,648	−40,512	−29,056
NET CASH USED IN INVESTING ACTIVITIES	−949,790	−1	−814,597	−3	−366,169
Proceeds from exercise of employee stock options	186,165	—	—	—	—
Borrowings from insurance finance indebtedness	406,751	487,516	565,172	783,799	924,389
Payments on insurance finance indebtedness	−677,903	−530,707	−684,123	−859,087	−415,806
Payments for taxes related to net share settlement of equity awards	−27,536	−97,379	—	—	—
Payments on finance lease liability, net of asset	−108,827	−107,963	−99,916	−51,850	−2,646
NET CASH USED IN FINANCING ACTIVITIES	−221,350	−248,533	−218,867	279,485	3
NET DECREASE IN CASH AND CASH EQUIVALENTS	−708,735	−2	−6	−8	−2
Interest	55,546	71,934	50,832	28,490	13,241
Income taxes	14,850	—	3,160	—	1,903

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is KORU Medical Systems, Inc.'s CIK number?

KORU Medical Systems, Inc.'s SEC CIK number is 0000704440 (704440). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find KORU Medical Systems, Inc.'s SEC filings?

All of KORU Medical Systems, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did KORU Medical Systems, Inc. last report earnings?

KORU Medical Systems, Inc. (KRMD) most recently filed an earnings 8-K with the SEC on May 6, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001161697-26-000107). This is KORU Medical Systems, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is KORU Medical Systems, Inc.'s most recent earnings 8-K?

KORU Medical Systems, Inc.'s latest earnings 8-K (Item 2.02) was filed May 6, 2026 under accession 0001161697-26-000107. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View KORU Medical Systems, Inc.'s latest earnings 8-K →
Look up any company's CIK number →